Focused On-demand Library for SMC5-SMC6 complex localization factor protein 2

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

PARTNER
Receptor.AI
 
UPACC
Q8IX21

UPID:
SLF2_HUMAN

ALTERNATIVE NAMES:
Smc5/6 localization factor 1

ALTERNATIVE UPACC:
Q8IX21; A8K950; B1AL17; Q5W0L8; Q6GMU6; Q9NPE8

BACKGROUND:
SMC5-SMC6 complex localization factor protein 2 plays a critical role in the DNA damage response, ensuring the integrity of the genome by facilitating the repair of UV-damaged DNA. It is part of a complex that recruits the SMC5-SMC6 complex to DNA lesions, crucial for viral restriction and maintaining genomic stability.

THERAPEUTIC SIGNIFICANCE:
The involvement of SMC5-SMC6 complex localization factor protein 2 in Atelis syndrome 1, characterized by severe developmental and physical anomalies, underscores its potential as a target for therapeutic intervention. Understanding its function could lead to novel treatments for diseases caused by genomic instability.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 208 of 8789